Case Study Simplifying and streamlining COPD treatment
|
|
- Clifton Wright
- 5 years ago
- Views:
Transcription
1 Case Study Simplifying and streamlining COPD treatment The production of this case study has been organised and sponsored by GlaxoSmithKline. The healthcare professional involved received no payment for his input.
2 Background Chronic obstructive pulmonary disease (COPD) is a respiratory condition which affects around three million people in the UK, however over two million sufferers are undiagnosed. 1 Around 30,000 people die from COPD in England each year, making it the fifth biggest killer. 2 COPD is responsible for 5% of all deaths in England and Wales. 3 The disease is characterised by irreversible airflow obstruction and symptoms include shortness of breath, cough, wheezing, a tight chest as well as over-production of phlegm and mucous. 1 People with COPD often suffer from exacerbations, where there is a rapid and sustained worsening of their symptoms, beyond normal day to day variations.¹ Patients with severe exacerbations may need to be hospitalised. 2 We report how simplification of the treatment protocol for COPD in Castle Point and Rochford Clinical Commissioning Group (CCG) led to streamlining of prescribing and more efficient follow-up of patients across the practices. Dr Marcus Lester, Prescribing Lead for COPD at Castle Point and Rochford CCG, was instrumental in implementing the current COPD guidelines within the CCG. He talks about how he approached the task. The goals of COPD treatment are to relieve dyspnoea, reduce long-term lung function decline, prevent and treat exacerbations, reduce hospitalisation and mortality, and improve exercise tolerance and health-related quality of life. 4 1
3 Local situation Castle Point and Rochford CCG includes 27 GP practices and 182,000 patients of a variable demographic. 5 The CCG has around 3,600 patients affected by COPD with a prevalence of 1.9%. 5 There were significant variations in COPD treatment protocols within the CCG. This was in part due to the wide array of possible therapies and the different guidelines in circulation. The COPD Guidelines were complicated as we received various guidelines from different organisations such as NICE and BTS. In the last couple of years we ve had a plethora of new inhalers and new drugs coming along, and things had become more complicated, so I decided to simplify it. There were huge variations in prescribing habits. All practices were doing things differently (including every GP and every nurse). The challenge was how we bring all this together. Better quality and better value for money could be achieved if we had clear and simple guidelines. Factors considered during the review For the Medicines Management Committee it was important to select drugs which not only have an acceptable benefit-risk profile, but also to select a treatment option that enables all drugs for the maintenance treatment of COPD to be delivered in the same, compatible device, across the treatment pathway. User-friendliness of a device for the patient was a major consideration. We weren t focusing on the cost of the drug alone - the device was really important too, as we wanted to streamline the options available for patients. Some of our patients are on a selection of treatments for exacerbations and for prevention. It is therefore important for them to have a device that they can use with their different types of treatment, be it an MDI or a DPI. We found that if a patient had too many different devices they would just use the device which they were most familiar with, and sometimes this would lead to them using an inappropriate inhaler for the situation they were in, which could have implications for patient safety. Furthermore, it was important to select a treatment that was easy to use. My registrars all tried to use the inhalers without any instructions. If they couldn t work out what to do with the inhaler then how would a patient know? That was the test we used to see how user-friendly a device is. If a patient is clear on how to use their device and they just have one device to use for their different medications, they may be more likely to stick to their treatment regimens. 2
4 Gaining consensus As with many situations that involve change, the Medicines Management Committee had to handle opposition to the new way of doing things. Some people said right from the beginning that streamlining guidelines would be impossible, so a number of individuals were completely opposed to the concept. The nurses felt that maybe their choices were being too restricted. The hospital was anxious about what we were doing and felt that what they were doing was being severely restricted. There were lots of discussions among our prescribing groups, our Medicines Management Teams and our Drugs and Therapeutics Committee, contributing to what was, overall, a robust process. There was room for compromise among stakeholders but going through every single committee meant that the process would become too slow and wouldn t achieve anything. There needed to be someone to drive things through in order to reach an outcome and in my role within the CCG I had to discuss the proposals with a lot of people to ensure we got a result. We were able to come to an agreement with the nurses and the hospitals, but we couldn t gain agreement from absolutely everyone. Communicating the guidelines Once the guidelines were established, there remained the task of how to communicate the revised treatment protocol and encourage adherence to it. We communicated the guidelines through the Prescribing Newsletter, on the Castle Point and Rochford CCG website and through meetings with nurses, pharmacists, and GPs as well as in our Time to Learn training sessions. The Time to Learn sessions included a 30-minute slot for Medicines Management where we would give updates on prescribing in the area. Pharmacists also attended the Time to Learn sessions. They have an important role to play as they do the new medicines reviews, so it was important to involve the pharmacists so that they too could communicate the guidelines to the prescribers. Adherence to the guidelines Healthcare professionals were encouraged to prescribe products that are on the guidelines and adherence to these guidelines was linked to an incentive scheme. We encouraged people to follow the guidelines through the Prescribing Incentive Scheme. This rewards practices for converting their patients to the CCG guidelines. We also send members of the Medicines Management team to support practices in converting to those guidelines. So if they follow the guidelines they are rewarded by being given money to spend on their practices. Monitoring of prescribing is done by checking what percentage of inhalers prescribed are those that feature on the guidelines. We appreciate that some practices may have variations in their prescribing based on the patient population they serve, or that there will always be patients on a drug that is not on the CCG guidelines, and we understand that. 3
5 Number of prescriptions Case Study: Simplifying and streamlining COPD treatment Changes to date We are getting better at diagnosing COPD and our recording of the prevalence of it has improved. This was helped by the Quality Outcomes Framework, support from the consultants but also the Time to Learn initiative. Streamlining the guidelines meant the patient wouldn t have to keep on swapping devices which they have to use in a completely different way when they use different medications. We always make sure that patients have an emergency pack for when they have exacerbations in COPD so that they have drugs on stand-by that they can take, rather than wait until they are bad and end up in hospital which is a disaster, as they get a lot worse. When comparing data in Q1 14/15 versus Q1 15/16, for LAMA, ICS/LABA and LAMA/LABA classes across Castle Point and Rochford CCG: Total spending is down circa 10, Total respiratory prescriptions written have increased by The average cost per inhaler has decreased by 2. 6 Revising and implementing the guidelines took us several months. Although this is work in progress, so far, streamlining of the different device options has improved since implementation of the guidelines. We have seen that the consistency of our prescribing is going up. Key success factors in implementing the guidelines In summary, the main factors that were instrumental in the success of the review and roll-out of the COPD guidelines were: Simplifying and streamlining the guidelines and keeping them logical and rational. Consistency in the messaging between what is said by the nurse, the pharmacist, the doctor, and the hospital so that the patient does not get confusing information. Getting all the stakeholders involved so that they can see and understand what is being done. The Ellipta was the device chosen by Castlepoint and Rochford CCG Fig 1. GSK report showing volume uptake of the Ellipta medicines across Castle Point and Rochford CCG Q Volume uptake of Ellipta* Q Q Q Q All Ellipta devices Relvar Ellipta (fluticasone furoate/vilanterol) 92/22 Incruse Ellipta (umeclidinium) 55 Relvar Ellipta (fluticasone furoate/vilanterol) 184/22 Anoro Ellipta (umeclidinium/vilanterol) 55/22 Q Q Relvar Ellipta 92/22 is licensed for both asthma and COPD. Relvar Ellipta 184/22 is licensed for asthma only. *Data Source: Prescribing data for England, Scotland, Wales and Northern Ireland 4
6 References 1. NICE. Chronic obstructive pulmonary disease in over 16s: diagnosis and management. cg101 (last accessed April 2017) 2. Department of Health. An Outcomes Strategy for Chronic Obstructive Pulmonary Disease (COPD) and Asthma in England. (last accessed April2017) 3. Rethinking COPD care in the UK: who cares? Lancet Respir Med. 2015;3:1. 4. Qaseem A, et al. Diagnosis and management of stable Chronic Obstructive Pulmonary Disease: A clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011;155: Quality Outcomes Framework Incidence and Population Figures. Available at: (last accessed April 2017) 6. GSK Data on File UK/RESP/0037/17 5
7 Relvar Ellipta (fluticasone furoate/vilanterol [as trifenatate]) Prescribing information (Please consult the full Summary of Product Characteristics (SmPC) before prescribing) Relvar Ellipta (fluticasone furoate/vilanterol [as trifenatate]) inhalation powder. Each single inhalation of fluticasone furoate (FF) 100 micrograms (mcg) and vilanterol (VI) 25 mcg provides a delivered dose of 92 mcg FF and 22 mcg VI. Each single inhalation of FF 200 mcg and VI 25 mcg provides a delivered dose of 184 mcg of FF and 22 mcg of VI. Indications: Asthma: Regular treatment of asthma in patients 12 years not adequately controlled on inhaled corticosteroids (ICS) and as needed short-acting inhaled ß2-agonists, where a longacting b2-agonist (LABA) and ICS combination is appropriate. COPD: Symptomatic treatment of adults with COPD with a FEV1<70% predicted normal (post-bronchodilator) and an exacerbation history despite regular bronchodilator therapy. Dosage and administration: Inhalation only. Asthma: Adults and adolescents 12 years: one inhalation once daily of Relvar 92/22 mcg for patients who require a low to mid dose of ICS in combination with a LABA. If patients are inadequately controlled then the dose can be increased to one inhalation once daily Relvar 184/22 mcg. Relvar 184/22 mcg can also be considered for patients who require a higher dose of ICS in combination with a LABA. Regularly review patients and reduce dose to lowest that maintains effective symptom control. COPD: one inhalation once daily of Relvar 92/22 mcg. Relvar 184/22 mcg is not indicated for patients with COPD. Contraindications: Hypersensitivity to the active substances or to any of the excipients (lactose monohydrate & magnesium stearate). Precautions: Pulmonary tuberculosis, severe cardiovascular disorders or heart rhythm abnormalities, thyrotoxicosis, uncorrected hypokalaemia, patients predisposed to low levels of serum potassium, chronic or untreated infections, diabetes mellitus, paradoxical bronchospasm. In patients with moderate to severe hepatic impairment 92/22 mcg dose should be used. Acute symptoms: Not for acute symptoms, use shortacting inhaled bronchodilator. Warn patients to seek medical advice if short-acting inhaled bronchodilator use increases. Therapy should not be abruptly stopped without physician supervision due to risk of symptom recurrence. Asthma-related adverse events and exacerbations may occur during treatment. Patients should continue treatment but seek medical advice if asthma symptoms remain uncontrolled or worsen after initiation of Relvar. Systemic effects: Systemic effects of ICSs may occur, particularly at high doses for long periods, but much less likely than with oral corticosteroids. Possible Systemic effects include: Cushing s syndrome, Cushingoid features, adrenal suppression, decrease in bone mineral density, growth retardation in children and adolescents. Eye symptoms such as blurred vision may be due to underlying serious conditions such as cataract, glaucoma or central serous chorioretinopathy (CSCR); consider referral to ophthalmologist. More rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children). Increased incidence of pneumonia has been observed in patients with COPD receiving inhaled corticosteroids. Risk factors for pneumonia include: current smokers, old age, patients with a history of prior pneumonia, patients with a body mass index <25 kg/m 2 and patients with a FEV1<50% predicted. If pneumonia occurs with Relvar treatment should be re-evaluated. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take Relvar. Interactions with other medicinal products: Interaction studies have only been performed in adults. Avoid ß-blockers. Caution is advised when co-administering with strong CYP3A4 inhibitors (e.g. ketoconazole, ritonavir, cobicistat-containing products). Concomitant administration of other sympathomimetic medicinal products may potentiate the adverse reactions of FF/VI. Relvar should not be used in conjunction with other longacting ß2-adrenergic agonists or medicinal products containing long-acting ß2-adrenergic agonists. Pregnancy and breast-feeding: Experience limited. Balance risks against benefits. Side effects: Very Common ( 1/10): headache, nasopharyngitis. Common ( 1/100 to <1/10): candidiasis of the mouth and throat, dysphonia, pneumonia, bronchitis, upper respiratory tract infection, influenza, oropharyngeal pain, sinusitis, pharyngitis, rhinitis, cough, abdominal pain, arthralgia, back pain, fractures, pyrexia, muscle spasms. Other important side effects include: Uncommon ( 1/1,000 to <1/100); blurred vision. Rare ( 1/10,000 to <1/1,000) paradoxical bronchospasm and hypersensitivity reactions including anaphylaxis, angioedema, rash, urticaria. See SmPC for other adverse reactions. Legal category: POM. Presentation and Basic NHS cost: Relvar Ellipta. 1 inhaler x 30 doses. Relvar Ellipta 92/ Relvar Ellipta 184/ Marketing authorisation (MA) nos. 92/22 mcg 1x30 doses [EU/1/13/886/002]; 184/22 mcg 1x30 doses [EU/1/13/886/005]. MA holder: Glaxo Group Ltd, 980 Great West Road, Brentford, Middlesex TW8 9GS, UK. Last date of revision: September UK/FFT/0227/15(3). Trademarks are owned by or licensed to the GSK group of companies GSK group of companies or its licensor Relvar Ellipta was developed in collaboration with Innoviva Inc. Incruse Ellipta (umeclidinium bromide) Prescribing information (Please consult the full Summary of Product Characteristics (SmPC) before prescribing) Incruse Ellipta 55mcg (umeclidinium) inhalation powder. Each single inhalation provides a delivered dose (the dose leaving the mouthpiece of the inhaler) of 55 micrograms umeclidinium (equivalent to 65 micrograms of umeclidinium bromide). Indications: Incruse is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). Dosage and administration: Inhalation only. One inhalation once daily of Incruse Ellipta at the same time of the day each day. Contraindications: Hypersensitivity to the active substances or to any of the excipients (lactose monohydrate and magnesium stearate). Precautions: Incruse Ellipta should not be used in patients with asthma. Treatment with Incruse Ellipta should be discontinued in the event of paradoxical bronchospasm and alternative therapy initiated if necessary. Cardiovascular effects may be seen after the administration of muscarinic receptor antagonists, therefore Incruse Ellipta should be used with caution in patients with severe cardiovascular disorders, particularly cardiac arrhythmias. Incruse Ellipta should be used with caution in patients with urinary retention or narrow angle glaucoma. No dosage adjustment is required in renal or mild to moderate hepatic impairment. Acute symptoms: Incruse Ellipta is not indicated for acute episodes of bronchospasm. Warn patients to seek medical advice if short-acting inhaled bronchodilator use increases, a re-evaluation of the patient and of the COPD treatment regimen should be undertaken. Interactions with other medicinal products: Co-administration with other long-acting muscarinic antagonists or medicinal products containing this active substance has not been studied and therefore, is not recommended. Fertility, pregnancy, and breast-feeding: No available human in vivo data. Balance risks against benefits. Side effects: Common ( 1/100 to <1/10): Nasopharyngitis, upper respiratory tract infection, urinary tract infection, sinusitis, headache, tachycardia, cough. Other Important side effects include. Uncommon ( 1/1,000 to <1/100): Atrial fibrillation, rhythm idioventricular, supraventricular tachycardia, supraventricular extrasystoles. Hypersensitivity reactions including rash, urticaria, pruritus. Not Known (cannot be estimated from available data): Glaucoma and vision blurred. Legal category: POM. Presentation and Basic NHS cost: Incruse Ellipta. 1 inhaler x 30 doses. Incruse Ellipta 55mcg Marketing authorisation (MA) nos. 55mcg 1x30 doses [EU/1/14/922/002]; MA holder: Glaxo Group Ltd, 980 Great West Road, Brentford, Middlesex TW8 9GS, UK. Last date of revision: April UK/INC/0001/17(1). Incruse and Ellipta are registered trademarks of the GlaxoSmithKline group of companies. All rights reserved. Anoro Ellipta (umeclidinium bromide/vilanterol [as trifenatate]) Prescribing information (Please consult the full Summary of Product Characteristics (SmPC) before prescribing) Anoro 55/22mcg (umeclidinium bromide /vilanterol [as trifenatate]) inhalation powder. Each single inhalation provides a delivered dose (the dose leaving the mouthpiece) of 55 micrograms umeclidinium (equivalent to 65 micrograms of umeclidinium bromide) and 22 micrograms of vilanterol (as trifenatate). Indications: Anoro is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). Dosage and administration: Inhalation only. One inhalation once daily of Anoro. Contraindications: Hypersensitivity to the active substances or to any of the excipients (lactose monohydrate and magnesium stearate). Precautions: Anoro should not be used in patients with asthma. Treatment with Anoro should be discontinued in the event of paradoxical bronchospasm and alternative therapy initiated if necessary. Cardiovascular effects may be seen after the administration of muscarinic receptor antagonists and sympathomimetics therefore Anoro should be used with caution in patients with severe cardiovascular disease. Anoro should be used with caution in patients with urinary retention, narrow angle glaucoma, convulsive disorders, thyrotoxicosis, hypokalaemia, hyperglycaemia and severe hepatic impairment. No dosage adjustment is required in renal or mild to moderate hepatic impairment. Acute symptoms: Anoro is not indicated for acute episodes of bronchospasm. Warn patients to seek medical advice if short-acting inhaled bronchodilator use increases, a re-evaluation of the patient and of the COPD treatment regimen should be undertaken. Interactions with other medicinal products: Avoid ß-blockers. Caution is advised when co-administering with strong CYP3A4 inhibitors (e.g. ketoconazole, clarithromycin, itraconazole, ritonavir, telithromycin). Anoro should not be used in conjunction with other long-acting ß2-adrenergic agonists or medicinal products containing long-acting muscarinic antagonists. Caution is advised with concomitant use with methylxanthine derivatives, steroids or non-potassium-sparing diuretics as it may potentiate possible hypokalaemic effect of ß2-adrenergic agonists. Fertility, pregnancy, and breast-feeding: No available data. Balance risks against benefits. Side effects: Common ( 1/100 to <1/10): urinary tract infection, sinusitis, nasopharyngitis, pharyngitis, upper respiratory tract infection, headache, cough, oropharyngeal pain, constipation and dry mouth. Other important side effects include: Uncommon ( 1/1,000 to <1/100) atrial fibrillation, supraventricular tachycardia, rhythm idioventricular, tachycardia, supraventricular extrasystoles, palpitations, and hypersensitivity reactions including rash. Rare ( 1/10,000 to <1/1,000) anaphylaxis, angioedema, and urticaria. Glaucoma, vision blurred, intraocular pressure increased and paradoxical bronchospasm. See SmPC for other adverse reactions. Legal category: POM. Presentation and Basic NHS cost: Anoro Ellipta. 1 inhaler x 30 doses. Anoro Ellipta 55/22mcg Marketing authorisation (MA) no. 55/22mcg 1x30 doses [EU/1/14/898/002]; MA holder: Glaxo Group Ltd, 980 Great West Road, Brentford, Middlesex TW8 9GS, UK. Last date of revision: Jan UK/UCV/0095/15(2). Anoro and Ellipta are registered trademarks of the GlaxoSmithKline group of companies. All rights reserved. Anoro was developed in collaboration with Innoviva Inc. Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to GlaxoSmithKline on
8 Case Study Simplifying and streamlining COPD treatment
The only COPD Triple Therapy delivered in a single daily inhalation. 1 Improvement in quality of life vs. ICS/LABA. 2
The only COPD Triple Therapy delivered in a single daily inhalation. 1 Improvement in quality of life vs. ICS/LABA. 2 Trelegy Ellipta is indicated for maintenance treatment in adult patients with moderate-to-severe
More informationInforMing the PAthway of COPD Treatment 1
InforMing the PAthway of COPD Treatment 1 A landmark trial in over 10,000 symptomatic COPD patients who had experienced at least one exacerbation in the last 12 months 1 (fluticasone furoate/umeclidinium/vilanterol)
More informationWhat is the current cost of COPD (Chronic Obstructive Pulmonary Disease) therapies?
What is the current cost of COPD (Chronic Obstructive Pulmonary Disease) therapies? Medicines in the COPD Ellipta portfolio are highlighted in orange on the graph below: Incruse Ellipta (umeclidinium)
More informationThis supplement has been developed in partnership with GlaxoSmithKline. Evidence Update
This supplement has been developed in partnership with GlaxoSmithKline cpd credits Evidence Update Respiratory A comparison of once-daily triple therapy with once-daily dual therapy in the treatment of
More informationIncruse Ellipta 55mcg (umeclidinium bromide) for the relief of symptoms in adult patients with Chronic Obstructive Pulmonary Disease (COPD):
Incruse Ellipta 55mcg (umeclidinium bromide) for the relief of symptoms in adult patients with Chronic Obstructive Pulmonary Disease (COPD): An introduction for Clinical Commisioning Groups and Health
More informationA comparison of once-daily triple therapy with once-daily dual therapy in the treatment of symptomatic COPD
A comparison of once-daily triple therapy with once-daily dual therapy in the treatment of symptomatic COPD The IMPACT trial EVIDENCE UPDATE This Guidelines supplement has been commissioned by GlaxoSmithKline.
More informationBudgetary Implications of Introducing the GSK Ellipta Portfolio for COPD in the UK
Budgetary Implications of Introducing the GSK Ellipta Portfolio for COPD in the UK Poster No. PRS20 Harding T 1, Thompson G 1, Mulley P 2 1 Health Outcomes, UK Pharma, GlaxoSmithKline, Stockley Park, UK
More informationRelvar Ellipta (fluticasone furoate and vilanterol as trifenatate) for the treatment of patients with COPD
Relvar Ellipta (fluticasone furoate and vilanterol as trifenatate) for the treatment of patients with COPD Medicines evidence pack to support formulary and guidelines decision making Prescribing information
More informationAnoro Ellipta 55/22mcg (umeclidinium and vilanterol) for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
Anoro Ellipta 55/22mcg (umeclidinium and vilanterol) for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) Medicines Evidence Pack to Support Formulary and Guidelines Decision Making Prescribing
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Dry Powder Inhaler, Nebuliser Suspension, pressurised Metered Dose Inhaler (pmdi)
Core Safety Profile Active substance: Budesonide Pharmaceutical form(s)/strength: Dry Powder Inhaler, Nebuliser Suspension, pressurised Metered Dose Inhaler (pmdi) P - RMS: DK/H/PSUR/0041/001 Date of FAR:
More information7.2 Part VI.2 Elements for a Public Summary
7.2 Part VI.2 Elements for a Public Summary 7.2.1 Part VI.2.1 Overview of disease epidemiology Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow limitation that is usually
More informationInitial U.S. Approval: 2013
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BREO ELLIPTA safely and effectively. See full prescribing information for BREO ELLIPTA. BREO ELLIPTA
More informationEvidence Summary to support COPD formulary decision making and guideline development
Evidence Summary to support COPD formulary decision making and guideline development Prescribing and adverse event reporting information can be found on the final page of this document. Trelegy and Ellipta
More informationPART VI: SUMMARY OF THE RISK MANAGEMENT PLAN
PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN VI.1 Summary of risk management plan for RELVAR ELLIPTA (fluticasone furoate/vilanterol) This is a summary of the risk management plan (RMP) for RELVAR ELLIPTA.
More informationAUSTRALIAN PRODUCT INFORMATION. BREO ELLIPTA (fluticasone furoate/vilanterol trifenatate) powder for inhalation
AUSTRALIAN PRODUCT INFORMATION BREO ELLIPTA (fluticasone furoate/vilanterol trifenatate) powder for inhalation 1 NAME OF THE MEDICINE Fluticasone furoate/vilanterol trifenatate 2 QUALITATIVE AND QUANTITATIVE
More informationNEW ZEALAND DATA SHEET SEREVENT Accuhaler
NEW ZEALAND DATA SHEET SEREVENT Accuhaler Salmeterol xinafoate (50 mcg per inhalation) Presentation SEREVENT Accuhaler is a moulded plastic device containing a foil strip with 60 regularly placed blisters
More informationFor the use only of Registered Medical Practitioners or a Hospital or a Laboratory. RELVAR ELLIPTA 100 mcg/25 mcg
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory RELVAR ELLIPTA 100 mcg/25 mcg Fluticasone Furoate and Vilanterol Powder for Inhalation QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationSee 17 for PATIENT COUNSELING INFORMATION and FDAapproved. Revised: 12/2017
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BREO ELLIPTA safely and effectively. See full prescribing information for BREO ELLIPTA. BREO ELLIPTA
More informationUtibron Neohaler. (indacaterol, glycopyrrolate) New Product Slideshow
Utibron Neohaler (indacaterol, glycopyrrolate) New Product Slideshow Introduction Brand name: Utibron Neohaler Generic name: Indacaterol, glycopyrrolate Pharmacological class: Long-acting beta2- agonist
More informationMEDICATION GUIDE ANORO ELLIPTA
MEDICATION GUIDE ANORO ELLIPTA [a-nor oh e-lip-ta] (umeclidinium and vilanterol inhalation powder) for oral inhalation What is the most important information I should know about ANORO ELLIPTA? ANORO ELLIPTA
More informationPatient Group Direction for SALBUTAMOL INHALER (Version 02) Valid From 1 October September 2019
Version Control This PGD has been agreed by the following organisations FCMS PDS Medical Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history
More informationA COPD medication delivery device option: an overview of the NEOHALER
A COPD medication delivery device option: an overview of the NEOHALER 2017 Sunovion Pharmaceuticals Inc. All rights reserved 9/17 RESP019-17 Indication and Boxed Warning INDICATION ARCAPTA NEOHALER (indacaterol)
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Relvar Ellipta 92 micrograms/22 micrograms inhalation powder, pre-dispensed 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each
More informationsummarising clinical guidelines for primary care Chronic obstructive pulmonary disease in over 16s: diagnosis and management
summarising clinical guidelines for primary care Chronic obstructive pulmonary disease in over 16s: diagnosis and management National Institute for Health and Care Excellence PREPRINT cpd credits The production
More informationRELVAR TM ELLIPTA TM QUALITATIVE AND QUANTITATIVE COMPOSITION
RELVAR TM ELLIPTA TM Fluticasone furoate/vilanterol QUALITATIVE AND QUANTITATIVE COMPOSITION Each single inhalation of fluticasone furoate/vilanterol provides a delivered dose of 92/22 micrograms of fluticasone
More informationSummary of the risk management plan (RMP) for Laventair (umeclidinium bromide and vilanterol)
EMA/258177/2014 Summary of the risk management plan (RMP) for Laventair (umeclidinium bromide and vilanterol) This is a summary of the risk management plan (RMP) for Laventair, which details the measures
More informationSummary of the risk management plan (RMP) for DuoResp Spiromax (budesonide / formoterol)
EMA/126654/2014 Summary of the risk management plan (RMP) for DuoResp Spiromax (budesonide / formoterol) This is a summary of the risk management plan (RMP) for DuoResp Spiromax, which details the measures
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationPART III: CONSUMER INFORMATION
PART III: CONSUMER INFORMATION Pr ANORO ELLIPTA umeclidinium (as bromide) and vilanterol (as trifenatate) dry powder for oral inhalation This leaflet is part III of a three-part "Product Monograph" published
More informationPART III: CONSUMER INFORMATION
PART III: CONSUMER INFORMATION Pr ANORO ELLIPTA umeclidinium (as bromide) and vilanterol (as trifenatate) dry powder for oral inhalation This leaflet is part III of a three-part "Product Monograph" published
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPrescribing guidelines: Management of COPD in Primary Care
Prescribing guidelines: Management of COPD in Primary Care Establish diagnosis of COPD in patients 35 years with appropriate symptoms with history, examination and spirometry (FEV1/FVC ratio < 70%) Establish
More informationSummary of the risk management plan (RMP) for Budesonide/Formoterol Teva (budesonide / formoterol)
EMA/639304/2014 Summary of the risk management plan (RMP) for Budesonide/Formoterol Teva (budesonide / formoterol) This is a summary of the risk management plan (RMP) for Budesonide/Formoterol Teva, which
More informationDr Stephen Child. Chief Medical Officer Southern Cross Health Society Auckland
Dr Stephen Child Chief Medical Officer Southern Cross Health Society Auckland 7:00-7:55 GlaxoSmithKline Breakfast Session - Hot Topics in Airways Disease: COPD and Asthma Hot Topics in Airways Disease:
More informationPRODUCT MONOGRAPH. fluticasone furoate/vilanterol (as trifenatate) dry powder for oral inhalation 100 mcg/25 mcg 200 mcg/25 mcg
PRODUCT MONOGRAPH PrBREO ELLIPTA fluticasone furoate/vilanterol (as trifenatate) dry powder for oral inhalation 100 mcg/25 mcg 200 mcg/25 mcg Inhaled Corticosteroid (ICS) and Bronchodilator (Long-Acting
More informationAlgorithm for the use of inhaled therapies in COPD
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationSummary of the risk management plan (RMP) for Vylaer Spiromax (budesonide / formoterol)
EMA/675937/2014 Summary of the risk management plan (RMP) for Vylaer Spiromax (budesonide / formoterol) This is a summary of the risk management plan (RMP) for Vylaer Spiromax, which details the measures
More informationSummary of the risk management plan (RMP) for Duaklir Genuair (aclidinium / formoterol fumarate dihydrate)
EMA/605453/2014 Summary of the risk management plan (RMP) for Duaklir Genuair (aclidinium / formoterol fumarate dihydrate) This is a summary of the risk management plan (RMP) for Duaklir Genuair, which
More informationAdjunct Associate Professor Robert Young
Adjunct Associate Professor Robert Young General Physician Auckland City Hospital 7:00-7:55 GlaxoSmithKline Breakfast Session - COPD New approaches in the management of COPD Dr Robert Young BMedSc MBChB
More informationTRELEGY ELLIPTA Fluticasone furoate/umeclidinium/vilanterol dry powder for oral inhalation
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION TRELEGY ELLIPTA Fluticasone furoate/umeclidinium/vilanterol dry powder for oral inhalation Read this leaflet carefully
More informationSERETIDE EVOHALER. Salmeterol/fluticasone propionate
Abbreviated Prescribing Information based on the International Prescribing Information and prepared to meet the requirements of the GSK International Pharmaceutical Promotional and Marketing Policy. SERETIDE
More informationPART III: CONSUMER INFORMATION
PART III: CONSUMER INFORMATION Pr ANORO ELLIPTA umeclidinium (as bromide) and vilanterol (as trifenatate) dry powder for oral inhalation This leaflet is part III of a three-part "Product Monograph" published
More informationElements for a Public Summary
VI.2 Elements for a Public Summary Fluticasone propionate / formoterol fumarate are available in pressarised metered dose inhalers (pmdi) under the brand names Flutiform, and in breath actuated inhalers
More informationPATIENT INFORMATION INCRUSE ELLIPTA
PATIENT INFORMATION INCRUSE ELLIPTA [IN-cruise e-lip-ta] (umeclidinium inhalation powder) for oral inhalation What is INCRUSE ELLIPTA? INCRUSE ELLIPTA is an anticholinergic medicine. Anticholinergic medicines
More informationRESPIRATORY CARE IN GENERAL PRACTICE
RESPIRATORY CARE IN GENERAL PRACTICE Definitions of Asthma and COPD Asthma is due to inflammation of the air passages in the lungs and affects the sensitivity of the nerve endings in the airways so they
More informationVentolin Accuhaler 200 micrograms salbutamol sulfate
Package Leaflet: Information for the User Ventolin Accuhaler 200 micrograms salbutamol sulfate Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationAlgorithm for the use of inhaled therapies in COPD Version 2 May 2017
Algorithm for the use of inhaled therapies in COPD This document has been revised by the Berkshire West Respiratory Network to support clinicians in selecting the most appropriate, cost effective treatments
More informationNEW ZEALAND DATA SHEET SERETIDE Accuhaler
NEW ZEALAND DATA SHEET SERETIDE Accuhaler Salmeterol xinafoate 50 mcg and Fluticasone (100 mcg, 250 mcg or 500 mcg) Presentation SERETIDE Accuhaler 50 mcg/100 mcg Moulded plastic device containing a foil
More informationChronic obstructive pulmonary disease
nice bulletin Chronic obstructive pulmonary disease NICE provided the content for this booklet which is independent of any company or product advertised nice bulletin Chronic obstructive pulmonary disease
More informationPATIENT INFORMATION BREO ELLIPTA
PATIENT INFORMATION BREO ELLIPTA [BRE-oh e-lip-ta] (fluticasone furoate and vilanterol inhalation powder) for oral inhalation What is BREO ELLIPTA? BREO ELLIPTA combines an inhaled corticosteroid (ICS)
More informationSerevent Diskus 50 microgram per metered dose inhalation powder, pre-dispensed
Agency Approval Date: Not applicable as IA Text Date: 27 April 2015 CO-0111149 GSK Logo Package Leaflet: Information for the User Serevent Diskus 50 microgram per metered dose inhalation powder, pre-dispensed
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationumeclidinium/vilanterol, 55/22 micrograms, inhalation powder (Anoro ) SMC No. (978/14) GlaxoSmithKline
umeclidinium/vilanterol, 55/22 micrograms, inhalation powder (Anoro ) SMC No. (978/14) GlaxoSmithKline 04 July 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationIPRAVENT Rotacaps (Ipratropium bromide)
Published on: 10 Jul 2014 IPRAVENT Rotacaps (Ipratropium bromide) Composition IPRAVENT Rotacaps Each capsule contains: Ipratropium Bromide BP, equivalent to Ipratropium Bromide (anhydrous) 40 mcg Excipient..q.s.
More informationumeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline
umeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline 07 November 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationWhat is in this leaflet. Before you use BREO ELLIPTA. What BREO ELLIPTA is used for. When you must not use it
BREO Fluticasone furoate 100 or 200 micrograms and vilanterol (as trifenatate) 25 micrograms per inhalation New Zealand Consumer Medicine Information What is in this leaflet Please read this leaflet carefully
More informationNovember Corporate Presentation 2017 INNOVIVA
November 2017 Corporate Presentation Forward-Looking Statements This presentation contains certain forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of
More informationP-RMS: SE/H/PSUR/0012/003
Core Safety Profile Active substance: Budesonide + Formoterol Pharmaceutical form(s)/strength: Inhalation powder, 80mcg/4,5mcg, 160mcg/4,5mcg, 320mcg/9mcg P-RMS: SE/H/PSUR/0012/003 Date of FAR: 05.05.2011
More informationCHALLENGES OF REAL LIFE ASTHMA MANAGEMENT. Dr Chris Lewis Respiratory Physician and Director of Prevocational Training Auckland District Health Board
CHALLENGES OF REAL LIFE ASTHMA MANAGEMENT Dr Chris Lewis Respiratory Physician and Director of Prevocational Training Auckland District Health Board CONFLICT OF INTEREST Employee of Auckland District Health
More informationIPRAVENT Respules/Respirator solution (Ipratropium bromide)
Published on: 19 Sep 2014 IPRAVENT Respules/Respirator solution (Ipratropium bromide) Composition IPRAVENT Respules Each 2 ml contains: Ipratropium Bromide BP equivalent to Ipratropium Bromide (anhydrous)
More informationNot available 100/6mcg 2 BD formoterol (Fostair MDI) 100/6mcg 33
COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP FLUTICASONE FUROATE/VILANTEROL COMBINATION INHALER - ASTHMA Policy agreed by Vale of York CCG (date) Drug, Treatment, Device name Fluticasone
More informationEach Salmex 50 microgram /500 microgram /dose contains approximately 12.9 mg of lactose
1. NAME OF THE MEDICINAL PRODUCT Salmex 50 microgram /100 microgram /dose inhalation powder, pre-dispensed Salmex 50 microgram /250 microgram /dose inhalation powder, pre-dispensed Salmex 50 microgram
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Seretide Diskus mite 50 microgram/100 microgram/ dose inhalation powder, pre-dispensed. Seretide Diskus 50 microgram/250 microgram/
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationRECENT MAJOR CHANGES
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TRELEGY ELLIPTA safely and effectively. See full prescribing information for TRELEGY ELLIPTA. TRELEGY
More informationPackage leaflet: Information for the user. Seretide Accuhaler
Package leaflet: Information for the user Seretide Accuhaler 50 microgram /100 microgram /dose inhalation powder, pre-dispensed. 50 microgram /250 microgram /dose inhalation powder, pre-dispensed. 50 microgram
More informationUMEC/VI vs. UMEC in subjects who responded to UMEC UMEC/VI vs. VI in subjects who responded to VI
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationEvidence Summary to support COPD formulary decision making and guideline development
Evidence Summary to support COPD formulary decision making and guideline development Prescribing and adverse event reporting information can be found on the final pages of this document. Anoro, and Ellipta
More informationPRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr TRELEGY ELLIPTA fluticasone furoate/umeclidinium (as bromide)/vilanterol (as trifenatate), dry powder for oral inhalation 100/62.5/25 mcg Inhaled
More informationNEW ZEALAND DATA SHEET
NEW ZEALAND DATA SHEET NAME OF MEDICINE OXIS TURBUHALER Eformoterol fumarate dihydrate (6 µg per inhalation) PRESENTATION OXIS TURBUHALER is a multidose, inspiratory flow driven, metered dose, dry powder
More informationDOSAGE AND ADMINISTRATION For oral inhalation only. (2) once daily. (2)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TRELEGY ELLIPTA safely and effectively. See full prescribing information for TRELEGY ELLIPTA. TRELEGY
More informationDo not use Easyhaler Salbutamol if you are allergic (hypersensitive) to: Salbutamol lactose
Package leaflet: Information for the patient user Easyhaler Salbutamol Sulphate 100 and 200 micrograms/dose inhalation powder Salbutamol sulphate (salbutamol) Read all of this leaflet carefully before
More informationPharmacist Objectives. Pulmonary Update. Outline. Technician Objectives. GOLD Guidelines. COPD Diagnosis 9/22/2017
Pharmacist Objectives Pulmonary Update Patty Marshik, PharmD Associate Professor University of New Mexico College of Pharmacy pmarshik@salud.unm.edu Discuss the new Global Initiative for Chronic Obstructive
More informationSummary of Product Characteristics
Summary of Product Characteristics 1. NAME OF THE MEDICINAL PRODUCT Setirenol, 50 microgram/250 microgram/dose, inhalation powder, predispensed Setirenol, 50 microgram/500 microgram/dose, inhalation powder,
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Flusarion Easyhaler 50 microgram/250 microgram/dose, inhalation powder Flusarion Easyhaler 50 microgram/500 microgram/dose, inhalation
More informationAgreed Core Safety Profile for Budesonide nasal spray suspension and Budesonide nasal powder
CSP Drug Budesonide Substance Date 13 Oct 2011 rev 11Nov Supersedes 18 Aug 2011 Agreed Core Safety Profile for DK/H/PSUR/0041/001 TABLE OF CONTENTS PAGE TITLE PAGE... 1 TABLE OF CONTENTS... 2 Introduction...
More informationFULL PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use INCRUSE ELLIPTA safely and effectively. See full prescribing information for INCRUSE ELLIPTA. INCRUSE
More informationMedicines Management of Chronic Obstructive Pulmonary Disease (COPD)
Medicines Management of Chronic Obstructive Pulmonary Disease (COPD) (Chronic & Acute) Guidelines for Primary Care Guideline Authors: Shaneez Dhanji (Wandsworth CCG) Samantha Prigmore (St George s Hospital)
More informationINCRUSE ELLIPTA PRODUCT INFORMATION
INCRUSE ELLIPTA PRODUCT INFORMATION NAME OF THE MEDICINE Umeclidinium (as bromide) Structure of umeclidinium bromide: OH N O Br Chemical Name: The chemical name of umeclidinium bromide is 1- Azoniabicyclo[2.2.2]octane,
More informationOXIS TURBUHALER 4.5 µg/dose and 9 µg/dose ASTRAZENECA
10-14 OXIS TURBUHALER 4.5 µg/dose and 9 µg/dose ASTRAZENECA formoterol fumarate dihydrate Inhalation powder Composition Each delivered dose (i.e. the dose leaving the mouthpiece) from Oxis Turbuhaler contains
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT DuoResp Spiromax 160 micrograms / 4.5 micrograms inhalation powder 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each delivered
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationOF PRODUCT CHARACTERISTICS
http://www.arx.com/about-cosign-digital-signaturessummary OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT {Budesonide/Formoterol Sandoz, 160 micrograms/4.5 micrograms/inhalation, inhalation
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT BiResp Spiromax 160 micrograms / 4.5 micrograms inhalation powder 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each delivered
More informationBREO ELLIPTA Fluticasone furoate 100 or 200 micrograms and vilanterol (as trifenatate) 25 micrograms per inhalation Consumer Medicine Information
BREO Fluticasone furoate 100 or 200 micrograms and vilanterol (as trifenatate) 25 micrograms per inhalation Consumer Medicine Information What is in this leaflet Please read this leaflet carefully before
More informationSummary of risk management plan for Ulunar Breezhaler (Indacaterol/glycopyrronium)
Part VI: Summary of the risk management plan Summary of risk management plan for Ulunar Breezhaler (Indacaterol/glycopyrronium) This is a summary of the RMP for Ulunar Breezhaler. The RMP details important
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE December 2014 Review Date: December 2017 Bulletin 206 : DuoResp Spiromax 160 / 4.5 and 320 / 9 budesonide & formoterol dry powder inhaler JPC Recommendations
More informationyour breathing problems worsen quickly. you use your rescue inhaler, but it does not relieve your breathing problems.
MEDICATION GUIDE ADVAIR DISKUS [ad vair disk us] (fluticasone propionate and salmeterol inhalation powder) for oral inhalation What is the most important information I should know about ADVAIR DISKUS?
More informationfluticasone propionate and salmeterol inhalation powder USP fluticasone propionate and salmeterol pressurised inhalation, suspension BP
Pr ADVAIR DISKUS fluticasone propionate and salmeterol inhalation powder USP Pr ADVAIR DISKUS 100 100 mcg fluticasone propionate and 50 mcg salmeterol (as the xinafoate salt) Pr ADVAIR DISKUS 250 250 mcg
More informationPackage leaflet: Information for the user
Package leaflet: Information for the user Irbesartan 75mg Film-coated Tablets Irbesartan 150mg Film-coated Tablets Irbesartan 300mg Film-coated Tablets irbesartan Read all of this leaflet carefully before
More informationPACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP
PACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP Brand or Product Name [Product name] Tablet 2mg [Product name] Tablet 4mg [Product name] Syrup 2mg/5ml Name and Strength of Active Substance(s)
More informationWhite powder in a light grey inhaler with a pale blue mouthpiece cover and a dose counter.
1. NAME OF THE MEDICINAL PRODUCT Relvar Ellipta 200/25 micrograms inhalation powder, pre-dispensed 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each single inhalation provides a delivered dose (the dose
More information